5. The combination of LHRH analogue and tamoxifen in premenopausal women with advanced breast cancer with skeletal metastases - updated results of a randomized study

The Breast ◽  
1995 ◽  
Vol 4 (3) ◽  
pp. 228
Author(s):  
R.W. Blarney
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Randomized Study ◽  
Premenopausal Women ◽  
Advanced Breast ◽  
Skeletal Metastases ◽  
Lhrh Analogue

Results of first line endocrine therapy for advanced breast cancer in premenopausal women with skeletal metastases only

The Breast ◽  
1993 ◽  
Vol 2 (3) ◽  
pp. 203-204 ◽  
Author(s):  
W. Jonat ◽  
M. Kaufmann ◽  
R. Blamey ◽  
A. Howell ◽  
J. Collins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Endocrine Therapy ◽  
Premenopausal Women ◽  
Advanced Breast ◽  
Skeletal Metastases ◽  
First Line

Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2− Advanced Breast Cancer

2018 ◽  
Vol 35 (9) ◽  
pp. 1356-1367 ◽  
Author(s):  
Anand A. Dalal ◽  
Geneviève Gauthier ◽  
Patrick Gagnon-Sanschagrin ◽  
Rebecca Burne ◽  
Annie Guérin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Premenopausal Women ◽  
Advanced Breast

Clinical Trial with 4-Hydroxy-17 α-methyl-19-nortestosterone in Advanced Breast Cancer

1964 ◽  
Vol 50 (6) ◽  
pp. 445-456 ◽  
Author(s):  
Sergio Di Pietro ◽  
Bruno Salvatori
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Side Effects ◽  
Antitumor Activity ◽  
Advanced Breast Cancer ◽  
Marked Effect ◽  
Premenopausal Women ◽  
Advanced Breast ◽  
Clinical Feature ◽  
Neoplastic Lesions

Twenty-two women with advanced breast cancer underwent clinical trial with a new hormonal compound, 4-hydroxy-17 α-methyl - 19 - nortestosterone (HMNT), in order to evaluate the antitumor activity of this steroid. The age of the patients ranged from 39 to 72 years; the compound was administrated i.m. at the dose of 50 mg a day, regularly and continuously, as long as a new progression of the neoplastic lesions was observed (in one case the treatment went on over a period of 13 months). An objective regression of the lesions was obtained in 8 of the 22 patients treated. The most impressive clinical feature of this new drug seems to consist in a more marked effect in premenopausal women, under 50 years of age. The compound proved to be practically free of virilizing action and of other unwanted side-effects, at least at the doses employed in this study.

scholarly journals MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Stephen Johnston ◽  
Miguel Martin ◽  
Angelo Di Leo ◽  
Seock-Ah Im ◽  
Ahmad Awada ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Randomized Study ◽  
Initial Therapy ◽  
Advanced Breast
Sign in / Sign up

Export Citation Format

Share Document